Merck/Bayer's Vericiguat Could Bring A New Dynamic For Heart Failure
The Phase III VICTORIA study evaluating the safety of the sGC stimulator met its primary endpoint.
You may also be interested in...
Merck & Co. Pushes Back On Modest Projections For Verquvo
Merck & Co.'s vericiguat, an sGC stimulator, was approved for heart failure but it enters a competitive space with a narrow indication.
Merck/Bayer’s Vericiguat Outcomes Data Less Impressive On Fuller Disclosure
Efficacy seen in reducing hospitalization in high-risk heart failure patients, but not in reducing the risk of cardiovascular death. Analysts say this portends a more niche opportunity for vericiguat.
Xarelto And Eylea Keep Bayer Buoyant
The German major's two leading products continue to perform well but there are not many potential blockbusters in the pipeline.